STOCK TITAN

ImmuCell Corporation - $ICCC STOCK NEWS

Welcome to our dedicated page for ImmuCell Corporation news (Ticker: $ICCC), a resource for investors and traders seeking the latest updates and insights on ImmuCell Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmuCell Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmuCell Corporation's position in the market.

Rhea-AI Summary

ImmuCell (Nasdaq: ICCC) reported a significant 111% year-over-year increase in product sales for Q1 2024, totaling $7.3 million. This marks the highest quarterly sales in the company's history. The trailing twelve-month sales also rose by 33%, reaching $21.3 million. Gross margin improved to 32%, up from 9% in Q1 2023. Despite these gains, the company reported a net loss of $438,000, a substantial improvement from the $2.3 million loss in the same period last year. EBITDA turned positive at $377,000 from a negative $1.6 million in Q1 2023. A backlog of $9.1 million in orders remains. However, cash reserves decreased slightly to $960,000. The FDA has delayed the approval of ImmuCell's Re-Tain® product due to pending inspectional observations at their contract manufacturer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.89%
Tags
-
Rhea-AI Summary

ImmuCell (Nasdaq: ICCC) will announce unaudited financial results for the quarter ended March 31, 2024 on May 14, 2024. The conference call to review the results is scheduled for May 15, 2024. Interested parties can access the call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. The Company expects no change to the preliminary sales results disclosed on April 9, 2024. Investors can review the updated Corporate Presentation slide deck on the Company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
-
Rhea-AI Summary
ImmuCell (ICCC) announces record-breaking total product sales of $7.3 million for the first quarter of 2024, marking an 111% increase from the same period in 2023. The company's total sales for the twelve-month period ended March 31, 2024, were $21.3 million, a 33% increase from the previous year. ImmuCell also revealed a backlog of orders worth approximately $9.1 million as of March 31, 2024, showing a significant growth in demand. The company is awaiting FDA approval to commercialize Re-Tain® and expects a response by May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
Rhea-AI Summary
ImmuCell Corporation (ICCC) reports a 30% increase in total sales for Q4 2023 compared to the same period in 2022. However, total sales for the year 2023 decreased by 6% due to production slowdowns caused by contamination events. The company aims to increase production capacity to achieve quarterly sales of $6 million or more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
-
Rhea-AI Summary
ImmuCell Corporation (ICCC) is set to release unaudited financial results for Q4 and 2023, with a conference call scheduled for February 28, 2024, at 9:00 AM ET. The Company expects no changes to the preliminary sales results disclosed earlier. Investors can access the call for updates and review the updated Corporate Presentation slide deck on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
-
Rhea-AI Summary
ImmuCell Corporation (Nasdaq: ICCC) announced preliminary unaudited sales results for the fourth quarter of 2023, showing a 30.3% increase in total sales compared to the same period in 2022. However, total sales for the year ended December 31, 2023, were 5.9% lower than the previous year due to lower production output caused by contamination events. The company aims to increase production output to meet demand and is working towards FDA approval to commercialize Re-Tain®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
Rhea-AI Summary
ImmuCell Corporation (Nasdaq: ICCC) Announces Unaudited Financial Results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
-
Rhea-AI Summary
ImmuCell Corporation announces preliminary sales results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
-
Rhea-AI Summary
ImmuCell submits CMC Technical Section for Re-Tain® to FDA, confirms achievement of objective
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
ImmuCell Corporation

Nasdaq:ICCC

ICCC Rankings

ICCC Stock Data

37.63M
5.58M
28.25%
13.49%
0.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PORTLAND

About ICCC

immucell corporation is a biotechnology company based out of portland maine. immucell's focus is to create scientifically-proven and practical products that result in a measurable economical impact on animal health and productivity in the dairy and beed industries.